UBS Downgrades Indevus Pharmaceuticals (IDEV) to Neutral
More News related to IDEV
- Endo Pharma (ENDP) Extends Period of Tender Offer for Shares of Indevus (IDEV)
- Indevus Pharma (IDEV) Announces NIH-Sponsored Study on PRO 2000 Shows Promise in HIV Prevention
- JMP Downgrades Indevus Pharma (IDEV) to Market Perform
- UBS Downgrades Indevus Pharmaceuticals (IDEV) to Neutral
- Unusual 11 Mid-Day Movers 1/6: IDEV, TXCO, ARM, ALD Higher; VDSI, CTDC, SMCI, ENDP Lower
UBS downgrades Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) from Buy to Neutral.
Indevus Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the acquisition, development, and commercialization of products to treat conditions in urology and endocrinology in the United States.
Related Categories
DowngradesStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
